Tianda Pharmaceuticals Management

Management criteria checks 4/4

Tianda Pharmaceuticals' CEO is Alan Fang, appointed in Feb 2017, has a tenure of 7.25 years. directly owns 56.72% of the company’s shares, worth HK$317.09M. The average tenure of the management team and the board of directors is 7.3 years and 10.7 years respectively.

Key information

Alan Fang

Chief executive officer

HK$45.0k

Total compensation

CEO salary percentage	n/a
CEO tenure	7.3yrs
CEO ownership	56.7%
Management average tenure	7.3yrs
Board average tenure	10.7yrs

Recent management updates

Recent updates

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

CEO

Alan Fang (54 yo)

7.3yrs

Tenure

HK$45,000

Compensation

Mr. Wen Quan Fang, also known as Alan, has been serves as Managing Director of Tianda Pharmaceuticals Limited since February 1, 2017. Mr. Fang has been Managing Director of Tianda Holdings Limited since Se...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Wen Quan Fang	Executive Chairman & MD	7.3yrs	HK$45.00k	56.72% HK$ 317.1m
Man Sang Lui	Executive Director	10.7yrs	HK$54.00k	no data
Man Yuk Wong	Financial Controller	4.3yrs	no data	no data
Tai On Lo	Company Secretary	no data	no data	no data

7.3yrs

Average Tenure

59yo

Average Age

Experienced Management: 455's management team is seasoned and experienced (7.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Wen Quan Fang	Executive Chairman & MD	20.6yrs	HK$45.00k	56.72% HK$ 317.1m
Man Sang Lui	Executive Director	10.7yrs	HK$54.00k	no data
Sung Hong Chiu	Independent Non-Executive Director	16.1yrs	HK$54.00k	no data
Yat-Fai Lam	Independent Non-Executive Director	19.7yrs	HK$54.00k	no data
Tao Zhong	Non-Executive Director	less than a year	no data	no data
Quanming Feng	Non-Executive Director	8.2yrs	no data	no data
Yanfang Xian	Independent Non-executive Director	less than a year	no data	no data

10.7yrs

Average Tenure

54yo

Average Age

Experienced Board: 455's board of directors are seasoned and experienced ( 10.7 years average tenure).

Tianda Pharmaceuticals Management

Management criteria checks 4/4

Key information

Recent management updates

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Announces Board Changes

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Recent updates

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age